Anthracycline-induced cardiac toxicity is not increased by dietary omega-3 fatty acids

Pharmacological Research

Volumn 47, Issue 2, 2003, Pages 111-117

  Germain, E ^a   Bonnet, P ^a   Aubourg, L ^a   Grangeponte, M C ^a   Chajes V ^a   Bougnoux, P ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Anthracycline; Cardiotoxicity; Polyunsaturated fatty acids; Rat

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIOXIDANT; ASCORBIC ACID; DOCOSAHEXAENOIC ACID; EPIRUBICIN; MENADIONE; OIL; OMEGA 3 FATTY ACID;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIET; DOSE CALCULATION; DOSE RESPONSE; ELECTROCARDIOGRAM; FAT INTAKE; FEMALE; GENDER; HEART FAILURE; HEMODYNAMICS; HISTOLOGY; IN VIVO STUDY; LIPID COMPOSITION; LIPID PEROXIDATION; MORTALITY; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; RAT STRAIN; TIME;

EID: 0037332301     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(02)00287-6     Document Type: Article

References (34)

1. Burns P., Spector A.A. Biochemical effects of lipids on cancer therapy. J. Nutr. Biochem. 5:1994;114-123.
2. Burns P., North J.A. Adriamycin transport and sensitivity in fatty acid-modified leukemia cells. Biochem. Biophys. Acta. 888:1986;10-17.
3. Bougnoux P. n-3 polyunsaturated fatty acids and cancer. Curr. Opin. Clin. Nutr. Metab. Care. 2:1999;121-126.
4. Zijlstra J.G., de Vries E.G., Muskriet F.A., Martini I.A., Timmer-Bosscha H., Mulder N.H. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin sensitive and resistant small-cell lung cell lines and on cytotoxicity in the tumor cell lines. Int. J. Cancer. 90:1987;850-856.
5. Petersen E.S., Kelley E.E., Modest E., Burns P. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM41.440. Cancer Res. 52:1992;6263-6269.
6. Kinsella J.E., Black J.M. Effects of polyunsaturated fatty acids on the efficacy of antineoplastic agents toward L5178Y lymphoma cells. Biochem. Pharmacol. 45:1993;1881-1887.
7. Sagar S., Das U.N. Gammalinolenic acid and eicosapentaenoic acid potentiate the cytotoxicity of anticancer drugs on human cervical carcinoma (HeLa) cells in vitro. Med. Sci. Res. 21:1993;457-459.
8. Tsai W.S., Nagawa H., Muto T. Differential effects of polyunsaturated fatty acids on chemosensitivity of NIH3T3 cells and its transformants. Int. J. Cancer. 70:1997;361-367.
9. Borgeson C., Pardini L., Pardini R., Reitz R. Effects of dietary fish oil on human mammary carcinoma and lipid-metabolizing enzymes. Lipids. 24:1989;290-295.
10. Shao Y., Pardini L., Pardini R.S. Enhancement of the antineoplastic effect of mitomycin C by dietary fat. Cancer Res. 54:1994;6452-6457.
11. Shao Y., Pardini L., Pardini R.S. Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids. 30:1995;1035-1045.
12. Shao Y., Pardini L., Pardini R.S. Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr. Cancer. 28:1997;63-73.
13. Bougnoux P., Germain E., Chajès V., Hubert B., Lhuillery C., Le Floch O.et al. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br. J. Cancer. 79:1999;1765-1769.
14. Germain E., Chajès V., Cognault S., Lhuillery C., Bougnoux P. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int. J. Cancer. 75:1998;578-583.
15. Germain E., Bonnet P., Lavandier F., Lhuillery C., Bougnoux P. Increased efficacy of epirubicin on NMU-induced mammary tumor in rats by dietary n-3 PUFA and oxidants without change in cardiac toxicity. Proc. Am. Ass. Cancer Res. 39:1998;311.
16. Mabille de Poncheville L., Chajès V., Germain E., Bougnoux P. Increased sensitivity of NMU-induced mammary tumors to anthracyclins by dietary DHA in rats. Proc. Am. Ass. Cancer Res. 41:2000;1270.
17. Allen A. The cardiotoxicity of chemotherapeutic drugs. Sem. Oncol. 19:1992;529-542.
18. Alderton P.M., Gross J., Green M.D. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52:1992;194-201.
19. Singal P.K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysioloy and prevention. FASEB J. 11:1997;931-936.
20. Lhuillery C., Bougnoux P., Groscolas R., Durand G. Time-course study of adipose tissue fatty acid composition during mammary tumor growth in rats with controlled fat intake. Nutr. Cancer. 24:1995;299-309.
21. Potier de Courcy G., Durand G., Abraham J., Guegen L. Recommandations sur les conditions d'alimentation des animaux de laboratoire (rats et souris). Sci. Aliment. 9:1989;209-217.
22. Noto V., Taper H.S., Yi-Hua J., Janssens J., Bonte J., De Loecker W. Effects of sodium ascorbate (Vitamin C) and 2-methyl-1,4-naphthoquinone (Vitamin K3) treatment on human tumor cell growth in vitro. Synergism of combined Vitamin C and K3 action. Cancer. 63:1989;901-906.
23. Ganzina F. 4-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat. Rev. 10:1983;1-22.
24. Lanza E., Rozza A., Favalli L., Monti E., Poggi P., Villani F. The rat model in the comparative evaluation of anthracyclines cardiotoxicity. Tumori. 75:1989;533-536.
25. Yeung T.K., Simmonds R.H., Hopewell J.W. The relative toxicity of intravenous and intraperitoneal doses of epirubicin. Cancer Chemother. Pharmacol. 24:1989;211-218.
26. Bertani T., Poggi A., Pozzoni R., Delaini F., Sacchi G., Thoua Y.et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab. Invest. 46:1982;16-23.
27. Van Hoesel Q., Steerenberg P., Dormans J., de Jong W., de Wildt D., Vos J. Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship. J. Natl. Cancer Inst. 76:1986;299-307.
28. Chan E.M., Thomas M.J., Bandy B., Tibbits G.F. Effects of doxorubicin, 4′-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. Can. J. Physiol. Pharmacol. 74:1996;904-910.
29. Palace V., Kumar D., Hill M., Khaper N., Singal P. Regional differences in non-enzymatic antioxidants in the heart under control and oxidative stress conditions. J. Mol. Cell Cardiol. 31:1999;193-202.
30. Chakrabarti K., Hopewell J., Wilding D., Plowman P. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane). Eur. J. Cancer. 37:2001;1435-1442.
31. Lii C.K., Ko Y.J., Chiang M.T., Sung W.C., Chen H.W. Effect of dietary Vitamin E on antioxidant status and antioxidant enzymes activities in Sprague-Dawley rats. Nutr. Cancer. 32:1998;95-100.
32. Matsui H., Morishima I., Hayashi K., Kamiya H., Saburi Y., Okumura K. Dietary fish oil does not prevent doxorubicin-induced cardiomyopathy in rats. Can. J. Cardiol. 18:2002;279-286.
33. Schjott J., Brurok H., Jynge P., Bjerve K.S. Effects of eicosapentaenoic acid and docosahexaenoic acid diet supplement on tolerance to the cardiotoxicity of epirubicin and to ischaemia reperfusion in the isolated rat heart. Pharmacol. Toxicol. 79:1996;65-72.
34. Hrelia S., Bordoni A., Biagi P.L. Role of gamma-linolenic acid in counteracting doxorubicin-induced damage in cultured rat cardiomyocytes. Prostaglandins Leukot. Essent. Fatty Acids. 64:2001;139-145.